Champions Oncology (NASDAQ:CSBR) Stock Price Down 1.8% - Time to Sell?

Key Points

• Shares fell 1.8% to $6.03 (intraday low $6.00) with just 3,485 shares trading—about 64% below average—while the stock sits near its 50‑day ($6.13) and 200‑day ($6.51) moving averages and has a market cap of $83.7M and a negative PE of -37.69.
• Analyst downgrade: Weiss Ratings cut Champions Oncology from "hold (c-)" to "sell (d-)", and the MarketBeat consensus rating is currently "Sell".
• Institutional investors own roughly 41.3% of the company, with several funds (e.g., Mink Brook, Essex, Vanguard, Acadian) recently initiating or increasing positions, including a new ~$555K stake by Mink Brook.

Champions Oncology, Inc. (NASDAQ:CSBR - Get Free Report)'s share price traded down 1.8% on Wednesday . The stock traded as low as $6.00 and last traded at $6.03. 3,485 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 9,735 shares. The stock had previously closed at $6.14.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Champions Oncology from a "hold (c-)" rating to a "sell (d-)" rating in a report on Monday, March 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of "Sell".

Champions Oncology Trading Down 1.8%

The firm has a market capitalization of $83.74 million, a PE ratio of -37.69 and a beta of 0.40. The company has a fifty day moving average price of $6.13 and a two-hundred day moving average price of $6.51.

Hedge Funds Weigh In On Champions Oncology

Several institutional investors have recently added to or reduced their stakes in the stock. Mink Brook Asset Management LLC acquired a new position in Champions Oncology in the 4th quarter valued at about $555,000. Essex Investment Management Co. LLC acquired a new position in Champions Oncology in the 4th quarter valued at about $126,000. Vanguard Group Inc. increased its position in Champions Oncology by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company's stock valued at $2,158,000 after acquiring an additional 6,229 shares during the period. XTX Topco Ltd acquired a new position in Champions Oncology in the 2nd quarter valued at about $103,000. Finally, Acadian Asset Management LLC increased its position in Champions Oncology by 28.7% in the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company's stock valued at $341,000 after acquiring an additional 8,814 shares during the period. Institutional investors and hedge funds own 41.30% of the company's stock.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.